7-Methyl-1H-indole-2-carboxylic acid, 95.0%, 1g

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole, 97%, 250mg

Diapositiva a contrasto di fase con fasatura per obiettivi di fase piano PLPH 10x e S40x

4-Decylaniline, 95.0%, 5g

4-bromo-2-chloronicotinonitrile, 95%, 1g

2-(4-Methoxyphenyl)pyridine>97.0%(GC)(T)5g

1,4-Dithiane-2,5-diol, 95.0%, 25g

tert-Butyl 4-cyano-4-(hydroxymethyl)piperidine-1-carboxylate, 95.0%, 25g

2-(1-Chloroethyl)-3,4-dihydroquinazolin-4-one, 97%, 100mg

2,4-Difluoro-6-methylbenzonitrile, 97%, 5g

{2-chloro-4-[(E)-(2,5-dioxoimidazolidin-4-ylidene)methyl]phenoxy}acetic acid, 95.0%, 1g

Ethyl 4-amino-2-thioxo-1,2-dihydro-pyrimidine-5-carboxylate, 97.0%, 10g

3-(5-Amino-4-cyano-3-methyl-pyrazol-1-yl)-benzoic acid ethyl ester, 95.0%, 1g